An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine

Launched by SINOVAC (DALIAN) VACCINE TECHNOLOGY CO., LTD. · Jun 26, 2024

Keywords

ClinConnect Summary

A total of 792 subjects aged 2 to 6 years including in per-protocol set (PPS) of immunogenicity assessment from previous phase Ⅲ clinical trial were enrolled. About 3.0ml of venous blood was collected at 6 and 10 years after booster immunization for antibody detection.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects in PPS of previous phase Ⅲ clinical trial of varicella vaccine;
• • The subjects and/or guardian can understand and voluntarily sign the informed consent form;
• • Proven legal identity.
• Exclusion Criteria:
• • Beyond the blood collection window period;
• • History of varicella or shingles;
• • History of varicella vaccination since phase Ⅲ clinical trial;
• • According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.